Integrum

Integrum Book Value Growth

The Book Value Growth of Integrum (INTEG B.ST) as of Oct 21, 2026 is 24.42 %. In the previous year, Book Value Growth was -0.52 % — a change of -4,807.46% (higher).

Book Value Growth

24.42 %

YoY

-4,807.46%

Last updated:

Book Value Growth of Integrum is 2025 24.42 % . Book Value Growth of Integrum was 2024 -0.52 % . It decreases by -4,807.46% higher compared to the previous year.

The Integrum Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2018
119.21 SEK
Jan 1, 2019
-30.49 SEK
Jan 1, 2020
47.81 SEK
Jan 1, 2021
2.22 SEK
Jan 1, 2022
558.61 SEK
Jan 1, 2023
-10.15 SEK
Jan 1, 2024
-0.52 SEK
Jan 1, 2025
24.42 SEK
The Integrum Book Value Growth history
YEARBook Value GrowthYoY
24.42 %-4,807.46%
-0.52 %-94.89%
-10.15 %-101.82%
558.61 %+25,011.32%
2.22 %-95.35%
47.81 %-256.81%
-30.49 %-125.58%
119.21 %-86.87%
907.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Integrum Stock analysis

What does Integrum do? Integrum AB generates revenue through the sale of medical devices, primarily the OPRA Implant System, which enables osseointegration for direct skeletal attachment of artificial limbs. The company also offers neural prosthetics technology, allowing bionic prostheses to connect directly to bone, nerves, and muscles, alongside a treatment method for phantom limb pain using machine learning, augmented reality, and virtual reality. Prosthetic components required to link the OPRA Implant System to external prostheses are sold as part of the product suite. Customers include individuals with amputations seeking advanced prosthetic solutions, with the company targeting medical professionals and healthcare providers who recommend and implement these systems. The OPRA Implant System, neural prosthetics, and phantom limb pain treatment are key revenue drivers, with the company focusing on high-end medical devices for specialized applications. Prosthetic components serve as complementary products, supporting the primary systems. The business model relies on direct sales to healthcare institutions and clinics specializing in prosthetics and rehabilitation, where the technology is integrated into patient care pathways. Integrum AB's product portfolio is centered around innovative medical solutions for amputees, with the OPRA Implant System as the flagship offering. The neural prosthetics and phantom limb pain treatment methods differentiate the company in the medical device market, addressing both functional and therapeutic needs. Sales of prosthetic components further enhance revenue streams by supporting the full integration of the implant system with external prosthetic devices. Integrum is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrum stock

Book Value Growth of Integrum is 24.42 % in 2025.

On Eulerpool you can find the complete historical development of Book Value Growth Integrum since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's Integrum historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Integrum

All Key Metrics — Integrum